Sientra (NASDAQ:SIEN)‘s stock had its “buy” rating reaffirmed by research analysts at Maxim Group in a report released on Monday. They presently have a $20.00 target price on the medical instruments supplier’s stock. Maxim Group’s target price would indicate a potential upside of 95.12% from the company’s previous close.

A number of other research analysts also recently issued reports on SIEN. ValuEngine downgraded Sientra from a “strong-buy” rating to a “buy” rating in a report on Thursday, January 24th. Zacks Investment Research upgraded Sientra from a “sell” rating to a “hold” rating in a research note on Wednesday, November 7th. Finally, BidaskClub lowered Sientra from a “hold” rating to a “sell” rating in a research report on Tuesday, November 13th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and nine have assigned a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus target price of $22.63.

Shares of NASDAQ SIEN traded down $0.01 during mid-day trading on Monday, reaching $10.25. 1,495 shares of the company’s stock were exchanged, compared to its average volume of 533,023. The firm has a market cap of $293.14 million, a P/E ratio of -3.63 and a beta of -0.03. The company has a debt-to-equity ratio of 0.36, a current ratio of 2.77 and a quick ratio of 2.34. Sientra has a twelve month low of $8.79 and a twelve month high of $26.79.

Institutional investors and hedge funds have recently modified their holdings of the business. Zurcher Kantonalbank Zurich Cantonalbank bought a new stake in Sientra during the 4th quarter worth approximately $29,000. Accredited Investors Inc. bought a new position in shares of Sientra in the third quarter valued at approximately $200,000. Tarbox Family Office Inc. grew its holdings in shares of Sientra by 595.3% in the third quarter. Tarbox Family Office Inc. now owns 9,734 shares of the medical instruments supplier’s stock valued at $232,000 after acquiring an additional 8,334 shares in the last quarter. MetLife Investment Advisors LLC grew its holdings in shares of Sientra by 55.2% in the third quarter. MetLife Investment Advisors LLC now owns 17,996 shares of the medical instruments supplier’s stock valued at $430,000 after acquiring an additional 6,397 shares in the last quarter. Finally, AQR Capital Management LLC grew its holdings in shares of Sientra by 41.5% in the third quarter. AQR Capital Management LLC now owns 19,345 shares of the medical instruments supplier’s stock valued at $462,000 after acquiring an additional 5,675 shares in the last quarter. 86.62% of the stock is owned by hedge funds and other institutional investors.

Sientra Company Profile

Sientra, Inc, a medical aesthetics company, develops and sells medical aesthetics products to plastic surgeons in the United States. It operates through two segments, Breast Products and miraDry. The company offers silicone gel breast implants for use in breast augmentation and breast reconstruction procedures; breast tissue expanders; and scar management products under the Sientra, AlloX2, Dermaspan, Softspan, and BIOCORNEUM brand names.

Further Reading: Is the Dow Jones Industrial Average (DJIA) still relevant?

Analyst Recommendations for Sientra (NASDAQ:SIEN)

Receive News & Ratings for Sientra Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sientra and related companies with MarketBeat.com's FREE daily email newsletter.